ウィメンズヘルス治療薬のインド市場の評価：薬剤別、適応症別、年齢層別、エンドユーザー別、地域別、機会、予測（2018年度～2032年度）

インドのウィメンズヘルス治療薬の市場規模は、2024年度の19億8,000万米ドルから2032年度に53億米ドルに達すると予測され、2025年度～2032年度の予測期間にCAGRで13.10%の成長が見込まれます。市場は、近年の技術の進歩と効率的なソリューションへの需要の高まりにより、大きく成長しています。同国の市場拡大の主な促進要因の1つは、座りがちな生活習慣や環境条件の変化により、人口の大部分がリプロダクティブヘルスを低下させていることです。

2024年6月、Orchid PharmaはCiplaと提携し、複雑尿路感染症（cUTI）、人工呼吸器関連肺炎（VAP）、院内肺炎（HAP）の治療薬として承認された画期的な複合抗生物質、セフェピム/エンメタゾバクタムを上市しました。この提携により、確実にインド全土にこの治療薬が広く流通しました。また、この提携によりOrchidの医薬品開発能力とCiplaの流通網が組み合わさり、この命を救う治療薬が効率的に医療従事者に届けられるようになりました。

当レポートでは、インドのウィメンズヘルス治療薬市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 インドのウィメンズヘルス治療薬市場の見通し（2018年度～2032年度）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 薬剤別
  • 適応症別
  • 年齢層別
  • エンドユーザー別
  • 地域別
  • 市場シェア分析（上位5社とその他、金額）（2024年度）
• 市場マップ分析（2024年度）
  • 適応症別
  • 年齢層別
  • エンドユーザー別
  • 地域別

第5章 需給分析

第6章 ポーターのファイブフォース分析

第7章 PESTLE分析

第8章 価格分析

第9章 市場力学

• 市場促進要因
• 市場の課題

第10章 市場の動向と発展

第11章 ケーススタディ

第12章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • AstraZeneca plc

第13章 戦略的提言

第14章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Women's Health Therapeutics Market, By Value, In USD Billion, FY2018-FY2032F
• Figure 2. India Women's Health Therapeutics Market Share (%), By Drug, FY2018-FY2032F
• Figure 3. India Women's Health Therapeutics Market Share (%), By Indication, FY2018-FY2032F
• Figure 4. India Women's Health Therapeutics Market Share (%), By Age-group, FY2018-FY2032F
• Figure 5. India Women's Health Therapeutics Market Share (%), By End-user, FY2018-FY2032F
• Figure 6. India Women's Health Therapeutics Market Share (%), By Region, FY2018-FY2032F
• Figure 7. By Drug Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 8. By Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 9. By Age-group Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 10. By End-user Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024

India women's health therapeutics market is projected to witness a CAGR of 13.10% during the forecast period FY2025-FY2032, growing from USD 1.98 billion in FY2024 to USD 5.30 billion in FY2032. India market for women's health therapeutics has grown significantly because of recent advancements in technologies and the growing demand for efficient solutions. One of the primary factors propelling market expansions in the country is most of the population's declining reproductive health owing to the sedentary lifestyles and shifting environmental conditions.

In June 2024, Orchid Pharma partnered with Cipla to launch Cefepime-Enmetazobactam, a breakthrough antibiotic combination approved for treating complicated Urinary Tract infections (cUTI), Ventilator-Associated Pneumonia (VAP), and Hospital-Acquired Pneumonia (HAP). This collaboration ensured widespread distribution of this treatment across India. In addition, the partnership combined Orchid's drug development capabilities with Cipla's distribution network, ensuring that this life-saving medication reaches healthcare providers efficiently.

Government Initiatives Fueling the Market Growth

Support from the government is crucial for the growth of women's health therapeutics market in India. Women's healthcare access, affordability, and awareness are receiving attention at the policy level, and many programs have been initiated to aid this. For example, Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) guarantees free prenatal checkups, while the adolescent health program focuses on the RKSK. Furthermore, the Ayushman Bharat Scheme enables fast financial aid to women facing costly procedures, including cancer treatments. Other regulations, such as drug price limits set by the NPPA, increase affordability of important drugs and medicines. There are also efforts to increase self-sufficiency in pharmaceuticals through the Production-Linked Incentive (PLI) Scheme, which promotes local businesses instead of foreign ones. The surge in funding directed toward women's health studies, the opening of new Janaushadhi Kendras, and changes in policy that favor menstrual and reproductive health care amplify the sales potential further. Such policy support guarantees usage of women healthcare services in India for both urban and rural areas, which is likely to bring forth many solutions for women's health issues. For instance, launched in Odisha, this universal health coverage program provides annual health coverage of USD 5,726 per family and USD 8,016 for female members. The scheme aims to enhance healthcare accessibility, particularly benefiting women in the state

Scientific Innovations Boosting Market Growth

Scientific research is a key driver in Women health therapeutics, resulting in sophisticated treatments, improved diagnostic technology, and targeted therapies. There has been an increase in government and private funding leading to faster paced research in endometriosis, polycystic ovarian syndrome (PCOS), infertility, and menopausal research. The rise of precision medicine and biotechnology has facilitated the development of personalized hormonal treatment for reproductive disorders, as well as non-invasive diagnostic tools. There has also been considerable progress in stem cell therapies and gene editing alongside drug delivery systems using nanotechnology for improving women's health in India. The Indian Council of Medical Research (ICMR) is collaborating with private pharma companies on clinical trials of new cancer therapies, fertility drugs, and HPV vaccines. These investments in R&D enable the advancement of woman healthcare by improving the efficacy, affordability, and accessibility of these treatments. For example, In December 2024, Novo Nordisk India advocated for an expedited launch of its weight-loss drug for women, called Wegovy, to compete with Eli Lilly's anticipated introduction of Mounjaro in 2025. Both drugs are GLP-1 receptor agonists, highly sought after for weight management.

Rising Incidence of Cancer Fueling the Market Growth

The increasing occurrence of cancer, particularly among women in India, is one of the major factors for the growth of the women's health therapeutics market. There is an increase in breast, cervical, ovarian, and endometrial cancers due to changes in lifestyle, genetic factors, and diagnosis at a later stage. As per the National Cancer Registry Programme (NCRP), the number of breast cancer cases in India has increased twofold over the past ten years, making it the most prevalent cancer among women. The surge in cases of HPV-induced cervical cancer recently prompted the government to implement vaccination drives across the country which stimulated demand for HPV vaccines. There is a growing pharmaceutical investment in oncology drugs due to the advances in targeted therapies, immunotherapy, and hormone therapy. The introduction of awareness programs on cancer, early detection, and increased access to cancer treatment through Ayushman Bharat is causing a rise in the need for novel and cost-effective women-centric cancer therapeutics. This growing burden of disease amplifies the demand for greater research, improved diagnostic tools, and more sophisticated treatment options. According to Observer Research Foundation, the number of cases of breast cancer increased steadily from 200,218 in 2019 to 221,579 in 2023; at the same time, the number of deaths from the disease increased from 74,481 to 82,429 in India. Even while incidence is far higher than fatality, mortality rates have been steadily rising, which suggests problems with early detection, access to treatment, and efficient management.

Future Market Scenario (FY2025 - FY2032F)

Many factors claim the growth of India women's health therapeutics market. Technological advancements give faster and more accurate results leading us to early diagnosis. Opportunity also lies in the increasing number of fertility concerns that the population is facing today. Promising initiatives of our government that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial. For instance, from primary healthcare facilities to sophisticated tertiary care hospitals, India currently has a vast healthcare infrastructure. One of the biggest healthcare systems in the world is expected to grow because of increased public and private sector investment. To increase access to high-quality healthcare for a larger portion of the population, developers are currently collaborating with healthcare providers to build cutting-edge facilities in tier 2 and tier 3 cities as well as metropolitan areas.

Key Players Landscape and Outlook

Key players in the women's health therapeutics industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) is an initiative which has expanded significantly, offering over 2,000 types of generic drugs and more than 300 surgical products by 2024. Notably, the scheme includes the "Janaushadhi Suvidha Oxy-Biodegradable Sanitary Napkin," providing affordable sanitary products to women across the country.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India Women's Health Therapeutics Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drug
    • 4.2.1.1. ACTONEL
    • 4.2.1.2. FORTEO
    • 4.2.1.3. Mirena
    • 4.2.1.4. NuvaRing
    • 4.2.1.5. Premarin
    • 4.2.1.6. Prolia
    • 4.2.1.7. Others
  • 4.2.2. By Indication
    • 4.2.2.1. Hormonal Infertility
    • 4.2.2.2. Cancer
      • 4.2.2.2.1. Cervical Cancer
      • 4.2.2.2.2. Breast Cancer
      • 4.2.2.2.3. Colorectal Cancer
      • 4.2.2.2.4. Ovarian Cancer
      • 4.2.2.2.5. Others
    • 4.2.2.3. Contraceptives
    • 4.2.2.4. Postmenopausal Osteoporosis
    • 4.2.2.5. Endometriosis and Uterine Fibroids
    • 4.2.2.6. Menopause
    • 4.2.2.7. Polycystic Ovarian Syndrome (PCOS)
    • 4.2.2.8. Others
  • 4.2.3. By Age-group
    • 4.2.3.1. Below 18
    • 4.2.3.2. 18 to 45
    • 4.2.3.3. Above 45
  • 4.2.4. By End-user
    • 4.2.4.1. Hospital Pharmacies
    • 4.2.4.2. Retail Pharmacies
    • 4.2.4.3. Online Pharmacies
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North
    • 4.2.5.2. South
    • 4.2.5.3. East
    • 4.2.5.4. West and Central
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Indication
  • 4.3.2. By Age-group
  • 4.3.3. By End-user
  • 4.3.4. By Region

All segments will be provided for all regions and countries covered

5. Demand Supply Analysis

6. Porter's Five Forces Analysis

7. PESTLE Analysis

8. Pricing Analysis

9. Market Dynamics

• 9.1. Market Drivers
• 9.2. Market Challenges

10. Market Trends and Developments

11. Case Studies

12. Competitive Landscape

• 12.1. Competition Matrix of Top 5 Market Leaders
• 12.2. SWOT Analysis for Top 5 Players
• 12.3. Key Players Landscape for Top 10 Market Players
  • 12.3.1. Merck & Co., Inc.
    • 12.3.1.1. Company Details
    • 12.3.1.2. Key Management Personnel
    • 12.3.1.3. Products and Services
    • 12.3.1.4. Financials (As Reported)
    • 12.3.1.5. Key Market Focus and Geographical Presence
    • 12.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 12.3.2. Pfizer Inc.
  • 12.3.3. GlaxoSmithKline plc
  • 12.3.4. F. Hoffmann-La Roche Ltd
  • 12.3.5. AbbVie Inc.
  • 12.3.6. Amgen Inc.
  • 12.3.7. Novartis AG
  • 12.3.8. Eli Lilly and Company
  • 12.3.9. Johnson & Johnson Services, Inc.
  • 12.3.10. AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us and Disclaimer